Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05889845 · ClinicalTrials.gov registry record · Phase 3
Candin for the Treatment of Common Warts
A Phase 3 study of Common Warts (Verruca Vulgaris), sponsored by Nielsen BioSciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 330
- Enrollment target
- 18
- Study locations
NCT05889845 is a Phase 3 study of Common Warts (Verruca Vulgaris) that has completed, run by Nielsen BioSciences. The registered enrollment target is 330 participants. The trial reports 18 study locations across 13 states.
The verdict
NCT05889845, a Phase 3 study of Common Warts (Verruca Vulgaris), has completed, sponsored by Nielsen BioSciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 330 participants
- Enrollment target
- 18
- Study locations
Study Summary
The goal of this clinical trial is to compare outcome in healthy subjects 12 years of age and older with at least 3, but no more than 20, common warts (Verruca vulgaris) following treatment with Candin or placebo. The main questions it aims to answer are: * does treatment with Candin result in better clearance of warts than placebo * how many injections are required to result in wart clearance Participants will * have one wart selected for injection every two weeks until clearance * return 12 weeks after wart clearance for assessment of durability of response
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Candin, Intradermal Solution
Study Locations (18)
Arkansas
- Arkansas Pediatric Clinic - Bryant
- Johnson Dermatology - Fort Smith
- Dermatology Clinic of Arkansas - Hot Springs
California
- Velocity Clinical La Mesa - La Mesa
- Long Beach Research - Long Beach
- Integrative Skin Research - Sacramento
Texas
- DermResearch - Austin
- Austin Institute for Clinical Research - Pflugerville
Alabama
- Cahaba Dermatology - Birmingham
Colorado
- Velocity Clinical Englewood - Englewood
Illinois
- Kaminska Dermatology - Chicago
Massachusetts
- Integrated Dermatology of Newton-Brighton - Brighton
Michigan
- Hamzavi Dermatology - Fort Gratiot
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2025-01-22 |
| Est. Completion | 2025-08-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05889845
The ClinicalTrials.gov registry entry for NCT05889845 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nielsen BioSciences, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Common Warts (Verruca Vulgaris) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05889845 reports 18 study locations spanning 13 distinct geographic areas - top geographies include Arkansas, California, Texas.
Frequently Asked Questions
What is clinical trial NCT05889845 about?
NCT05889845 is a clinical study titled "Candin for the Treatment of Common Warts". The goal of this clinical trial is to compare outcome in healthy subjects 12 years of age and older with at least 3, but no more than 20, common warts (Verruca vulgaris) following treatment with Candin or placebo. The main questions it aims to answer are: * does treatment with Candin result in bett...
What is the current status of trial NCT05889845?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 330 participants. The study started on 2025-01-22. Estimated completion is 2025-08-27.
What conditions does trial NCT05889845 study?
This clinical trial studies the following conditions: Common Warts (Verruca Vulgaris).
What interventions are being tested in trial NCT05889845?
The interventions under investigation include: Placebo (DRUG), Candin, Intradermal Solution (DRUG).
Who is sponsoring clinical trial NCT05889845?
This trial is sponsored by Nielsen BioSciences, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05889845 being conducted?
This trial has 18 study locations across Alabama, Arkansas, California, Colorado, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Common Warts (Verruca Vulgaris)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.